BPTH Bio-Path Holdings Inc.

19.11
-2.87  -13%
Previous Close 21.98
Open 19.21
Price To Book 38.99
Market Cap 47902807
Shares 2,507,239
Volume 1,109,181
Short Ratio
Av. Daily Volume 4,789,073

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced December 29, 2017.
Prexigebersen
Chronic myelogenous leukemia (CML)
Phase 2 presentation at ASH December 2018. CR 4/17. Increased to 5/17 following updated analysis - March 6, 2019.
Prexigebersen - BP1001
Acute myeloid leukemia (AML)

Latest News

  1. Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons
  2. Bio-Path Holdings Reports Full Year 2018 Financial Results
  3. Bio-Path Holdings, Inc. to Host Earnings Call
  4. Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019
  5. Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
  6. Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock
  7. The Secret To Trading Stocks Like Bio-Path That Helped Me Quit My Desk Job And Make Thousands
  8. The Device Market That Drove One Company From $2.50 to $65 Has a New Entrant
  9. Traders Mystified by 3000% Surge in Shares of Cancer-Drug Maker
  10. UPDATE: Bio-Path stock gains another 130% on Thursday
  11. Bio-Path Holdings Updates Clinical Trial Data and it Sounds Promising
  12. Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today
  13. Under the Radar Cannabis Stock-THC Therapeutics, Inc.
  14. Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
  15. Is Bio-Path Holdings, Inc.’s (NASDAQ:BPTH) CEO Pay Justified?
  16. Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting
  17. Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
  18. Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market
  19. Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market
  20. Bio-Path Holdings Announces 1-for-20 Reverse Stock Split